Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
amylin is an insulin sensitizer https://www.sciencedirect.com/science/article/pii/S2212877820301836#sec5 |
Retatrutide developped for diabetes as well: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext#%20 |
||
| Line 125: | Line 125: | ||
|list1= |
|list1= |
||
*[[Tirzepatide]] |
*[[Tirzepatide]] |
||
{{navbox|child| |
|||
group1=Triple |
|||
|list1=GLP-1/GIP/[[Glucagon receptor|GCGR]] triple agonists |
|||
* [[Retatrutide]] |
|||
}} |
|||
}} |
}} |
||
Revision as of 19:40, 3 December 2023
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.